All you need to know about tafasitamab for DLBCL

  • Medscape

  • curated by Pavankumar Kamat
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In an interview with Medscape, Ann S. LaCasce, MD, a lymphoma specialist, talks about tafasitamab-cxix (Monjuvi) in combination with lenalidomide, recently approved by the US Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 

Key points

  • Almost 40% of patients with DLBCL will have relapsed or refractory disease.
  • The pace of DLBCL can be highly variable, with some patients responding to multiple lines of therapy, whereas others experience rapidly progressive refractory disease.
  • More than half of patients do not fit the eligibility criteria for autologous stem cell transplant (ASCT).
  • Tafasitamab-cxix is an appropriate option for patients who are ineligible for potentially curative approaches, including ASCT and chimeric antigen receptor (CAR) T-cell therapy.
  • Tafasitamab-cxix was approved on the basis of the phase 2 L-MIND study of tafasitamab plus lenalidomide in patients who were ineligible for ASCT and had received 1-3 prior regimens.
  • The overall and complete response rates were 60% and 43%, respectively, and median PFS was approximately 1 year.
  • The most common adverse events were infusion reactions and myelosuppression.
  • Tafasitamab plus lenalidomide regimen requires frequent visits, particularly during the first 3 months and then every other week until progression. 
  • Because tafasitamab therapy needs to be continued until progression, the cumulative cost is likely to be very high; however, all other therapies are also costly.
  • Other drugs under development or trials for relapsed or refractory DLBCL include novel CAR T-cell therapies such as lisocabtagene maraleucel, bispecific antibodies such as REGN1979 and mosunetuzumab, combinations with CD47 antibodies, and loncastuximab tesirine.